Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

vector

TCR redirected T cells for cancer therapy 1:46
TCR redirected T cells for cancer therapy
Chiara Bonini • 1 Apr 2022
Impact of COVID-19 on the advanced therapies sector 1:34
Impact of COVID-19 on the advanced therapies sector
Christian Schneider • 29 Oct 2021
Remaining issues in developing advanced therapies 2:12
Remaining issues in developing advanced therapies
Christian Schneider • 29 Oct 2021
Addressing the regulatory barriers advanced therapies face 1:19
Addressing the regulatory barriers advanced therapies face
Christian Schneider • 29 Oct 2021
The landscape of cell therapy for solid tumors 1:22
The landscape of cell therapy for solid tumors
Sven Kili • 5 Oct 2021
Vector-based therapies for metabolic disorders 3:09
Vector-based therapies for metabolic disorders
Gloria Gonzalez-Aseguinolaza • 18 May 2021
Novel oncolytic Ad6 vectors for cancer therapy 2:05
Novel oncolytic Ad6 vectors for cancer therapy
Margarita Romanenko • 13 May 2021
The need for next-gen AAV vectors 1:14
The need for next-gen AAV vectors
Arun Srivastava • 17 May 2021
NextGen & GenX AAV vectors for DMD gene therapy 3:49
NextGen & GenX AAV vectors for DMD gene therapy
Arun Srivastava • 18 May 2021
Synthetic AAV vectors for gene therapy of hemophilia in children 4:15
Synthetic AAV vectors for gene therapy of hemophilia in children
Arun Srivastava • 18 May 2021
The future impact of COVID-19 on the gene therapy sector 2:12
The future impact of COVID-19 on the gene therapy sector
Nicole Faust • 9 Apr 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy